ArticleScientific reports2026
Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine axis-mediated recruitment of leukocytes that drive disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cross-species comparative spatial transcriptomics of hair follicle-T cell interactions identifies conserved drivers of cutaneous lupus erythematosus skin disease and associated hair loss.Nature communications · 2026Article
- Spatial characterization of skin lesions in discoid and systemic lupus erythematosus.Nature communications · 2026Article
- Remote Skin and Blood Sampling for Translational Connective Tissue Disorder Research: A Proof-of-Concept Pilot Study.JID innovations : skin science from molecules to population health · 2026Article
- Keratinocyte VISTA attenuates UV light-induced skin injury by suppressing cutaneous type I interferon (IFN-I) response.bioRxiv : the preprint server for biology · 2025Article
- Keratinocytes - Amplifiers of Immune Responses in Systemic Lupus Erythematosus.Current rheumatology reports · 2024Review
Corrections and comments
- Update of
Authors and funding
29 authors.
Funding
Abstract
Chemokines play critical roles in the recruitment and activation of immune cells in both homeostatic and pathologic conditions. Here, we examined chemokine ligand-receptor pairs to better understand the immunopathogenesis of cutaneous lupus erythematosus (CLE), a complex autoimmune connective tissue disorder. Our objectives were to investigate the immunopathogenesis and therapeutic targets of interface dermatitis in patients with cutaneous lupus erythematosus. Four subacute cutaneous lupus erythematosus (SCLE), 4 discoid lupus erythematosus (DLE) and 3 healthy margin controls were enrolled for archival tissue sampling for spatial transcriptomics and proteomics. Seven CLE (4 SCLE, 3 DLE) patients and 3 healthy controls were enrolled for fresh tissue blister biopsy sampling of 184 protein analytes in interstitial skin fluid and serum using targeted proteomics, as well as spectral flow cytometry analysis for interface dermatitis cells. An additional 6 CLE and 6 healthy blood donors were enrolled for functional chemotaxis assays. Spatial and targeted proteomics data confirmed elevation of interferon (IFN) and IFN-inducible CXCR3 chemokine ligands. Comparing involved to uninvolved epidermal keratinocytes in CLE samples revealed upregulation of essential inflammatory response genes in areas near interface dermatitis, including AIM2. Targeted proteomics data confirmed upregulation of Caspase 8, IL-18 which is the final product of AIM2 activation, and induced chemokines including CCL8 and CXCL6 in CLE lesional samples. Chemotaxis assays using peripheral blood mononuclear cells (PBMCs) from healthy and lupus donors revealed that T cells respond to CXCL9 and CXCL11, whereas CD14+CD16+ monocyte populations are more sensitive to CXCL6 via CXCR1 and CD14+ monocytes are more sensitive to CCL8 via CCR2. Furthermore, in vitro blocking assays revealed that hydroxychloroquine blocks CCL8 driven CD14+ monocyte migration, whereas reparixin blocks CXCL6 driven CD14+CD16+ monocyte migration. Taken together, our data map a pathway from keratinocyte injury to lymphocyte recruitment in CLE via AIM2-Casp8-IL-18-CXCL6-CXCR1 CD14+CD16+ monocyte recruitment, CCL8-CCR2 CD14+ monocyte recruitment, and IFNG/IFNL1-CXCL9/CXCL11-CXCR3 T cell recruitment, and suggest a mechanism by which hydroxychloroquine blocks CCR2+ CD14+ monocyte migration. We also identify reparixin and its derivatives as potential novel inhibitors of CXCR1+ CD14+CD16+ monocyte migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.